Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences reports early Phase 2 bladder cancer data for dabogratinib, 60 mg dose chosen

Positive Impact 3 of 5 product/contract Written later

Tyra Biosciences reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, as of an August 31, 2026 data cutoff. The company selected 60 mg once daily as the potential dose for a planned registrational adjuvant program, with a registrational study expected to start in 2027, subject to health authority feedback. Results are early, based on 26 evaluable participants, and the company notes they may change with further follow-up.

Key points

  • SURF302 3-month overall response rate was 79% (11/14) at 60 mg once daily and 67% (8/12) at 50 mg once daily
  • Grade 3 treatment-emergent adverse events occurred in 14% (3 of 22) at 60 mg and 9% (2 of 22) at 50 mg; no Grade 4 or 5 events were reported
  • The company plans to meet health authorities on Phase 3 design and dose selection and expects to start a registrational adjuvant study in 2027
  • Company estimates an IR NMIBC market opportunity of greater than $5 billion, based on third-party market research and assumptions

The filing

CompanyTyra Biosciences, Inc. (TYRA)
Form8-K, current report
Filed with the SECSep 9, 2026, 7:10 AM ET
Accession number0001193125-26-385886

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.